Theralases innovative anti cancer technology validated at major international conferences
Press Release Theralase’s Innovative Anti-Cancer Technology Validated at Major International ConferencesToronto, Ontario – April 19, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that itsinnovative Photo Dynamic Compound (PDC) technology has been accepted for presentation at twomajor international scientific conferences. Acceptance at these conferences validates the significanceof the technology and its efficacy in the destruction of cancer cells in research performed byTheralases internationally acclaimed scientists.The efficacy of the anti-cancer Photo Dynamic Compound technology will be presented at LASER Worldof Photonics conference in Munich, Germany on May 15, 2013.The effective destruction of bacteria using Theralase’s light activated Photo Dynamic Compoundtechnology will be presented at Photonics North conference in Ottawa, Canada on June 3, 2013.In further developments, Theralase’s Chief Scientific Officer, Dr. Arkady Mandel has been elected tothe Editorial Board of Photonics & Lasers in Medicine (PLM) journal and chosen as issue editor of PLMfor the Low Level Laser Therapy (LLLT) issue. PLM is an internationally peer-reviewed journal, whichpublishes clinical and scientific studies concerned with the clinical and scientific application of lasersand biophotonics in medicine for diagnostic and therapeutic purposes. PLM recently featured theclinical success of Theralase’s pivotal randomized placebo controlled clinical trial entitled, “LaserTherapy Applications for Osteoarthritis and Chronic Joint Pain.”Roger Dumoulin-White, President and CEO of Theralase said, "I am pleased that Theralase’s scientificand clinical research has been recognized and acclaimed by two of the finest international scientificconferences and has been published in a peer reviewed medical journal. Theralase is committed to theearly commercialization of its patented light activated Photo Dynamic Compounds in the areas of anti-cancer and anti-bacterial applications to generate substantial revenue increases for the Company. Toaccelerate this process, we are actively looking to collaborate with strategic partners to furtherdevelop our technologies and increase shareholder value. Theralase’s strong PDC pipeline hasscientifically proven that our PDC technology is capable of consistently producing cell kill levels of100%, even at very low concentrations, across a wide range of cancers and bacteria. In fact, our PDCshave been proven to be significantly more effective in destroying cancer cells and bacteria thancurrently FDA approved Photo Dynamic Compounds.”About Theralase Technologies Inc.:Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralasetechnology is safe and effective in treating pain, inflammation and for tissue regeneration of neuralmuscular skeletal conditions and wound healing. Theralase is currently developing patented PhotoDynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses whenlight activated by Theralase’s proprietary laser technology.
Press ReleaseFor further information please visit www.theralase.com , regulatory filings may be viewed by visitingwww.sedar.com.This press release contains forward-looking statements, which reflect the Companys current expectations regarding future events. The forward-lookingstatements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation toupdate these forward-looking statements.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) acceptsresponsibility for the adequacy or accuracy of this release.For More InformationRoger Dumoulin-WhitePresident & CEO416-699-LASE (5273) ext. email@example.comKristina HacheyChief Financial Officer416-699-LASE (5273) ext. firstname.lastname@example.orgArkady MandelChief Scientific Officer416-699-LASE (5273) ext. email@example.comGreg BewshDirector of Investor Relations416-699-LASE (5273) ext. firstname.lastname@example.org